

## PRECONFERENCE

Friday, **July 25th**



### WORKSHOP SESSION

**8:00 am - 12:00 pm (EDT)**

#### **Basics of Genetic Analysis.**

The workshop will provide an immersive introduction to the fundamentals of genetic analysis within the framework of brain imaging genetics research. Tailored for participants interested in exploring the interplay between genetic data and imaging-based studies, the sessions will integrate theoretical concepts with hands-on practice to provide a comprehensive learning experience.

#### SPEAKERS

**Krishna Rani Kalari, PhD**

**Yuetiva Robles, PhD**

**Emma Luckett, PhD**

**Karunya Kandimalla, PhD**

**Natalia Vilor-Tejedor, PhD**

#### ORGANIZING COMMITTEE

**Tavia E Evans, PhD - Natalia Vilor-Tejedor, PhD**

**Junhao Wen, PhD - David M Cash, PhD**

**Tobey J. Betthausen, PhD**

#### SESSION DETAILS

**WESTIN HARBOUR CASTLE (Pier 2).**

**AAIC**

Sunday, **July 27th** (1/2)



**POSTERS**

**ONLINE**

**Detecting early memory changes in preclinical Alzheimer's disease using TabCAT Favorites Test: data from the European Prevention of Alzheimer's Disease (EPAD) cohort.**

PRESENTING AUTHOR

**Anna Brugulat-Serrat, PhD**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Sunday-118**

**Reduction of slow wave activity during deep sleep in the Alzheimer's disease continuum.**

PRESENTING AUTHOR

**Núria Tort-Colet, PhD**

AREA

Basic Science and Pathogenesis:  
Human Neuropathology.

**Sunday-385**

**Graph network properties associated with Alzheimer's pathological hallmarks early in the disease continuum.**

PRESENTING AUTHOR

**Aldana Lizarraga, MSc**

AREA

Biomarkers: Neuroimaging.

**Sunday-449**

**Integrating chromosome 19 local ancestry in genetic-regional association studies reveal novel ancestry-specific variants associated to amyloid and hippocampal volume.**

PRESENTING AUTHOR

**Tavia Evans, PhD**

AREA

Biomarkers: Neuroimaging.

**ONLINE**

**Synergistic Effects of Plasma p-tau217 and GFAP on Neurodegeneration and Cognitive Decline in Cognitively Unimpaired Individuals.**

PRESENTING AUTHOR

**Raffaele Cacciaglia, PhD**

AREA

Biomarkers: Neuroimaging.

**Sunday-102197**

**Olfactory dysfunction relates to lower glymphatic functioning as measured by DTI-ALPS in cognitively unimpaired individuals with family history of dementia.**

PRESENTING AUTHOR

**Gonzalo Sánchez-Benavides, PhD**

AREA

Clinical Manifestations: Neuropsychiatry and Behavioral Neurology.

**Explore BBRC's participation  
at the AAIC 2025**

**July 27 — 31**  
TORONTO (CANADA) AND ONLINE

**AAIC**

Sunday, **July 27th** (2/2)



**FEATURED  
RESEARCH  
SESSION**

**9:00 - 10:30 am (EDT)**

**Predicting cognitive  
trajectories in asymptomatic  
individuals at-risk of AD:  
insights from a multi-platform  
plasma proteomics study.**

PRESENTING AUTHOR

**Federica Anastasi, PhD**

SESSION DETAILS

Proteomic Signature Prediction And  
Mechanistic Insights To Cognitive Decline.

📍 ROOM 105 — Metro Toronto Convention  
Centre.

**2:00 - 3:30 pm (EDT)**

**Shorter leukocyte telomere  
length is associated with  
distinct CSF biomarker  
dynamics across early AD  
stages in at-risk individuals.**

PRESENTING AUTHOR

**Blanca Rodríguez-Fernández, PhD**

SESSION DETAILS

Integrative Investigation of Alzheimer's Disease  
and Aging Through Imaging Genetics and  
Proteomics.

📍 ROOM 105 — Metro Toronto Convention  
Centre.



**AAIC**

Monday, July 28th (1/2)



**POSTERS**

**Monday-469**

**Distinct risk profiles drive white matter hyperintensities progression and relate to cognitive worsening in asymptomatic individuals at risk of Alzheimer's disease.**

PRESENTING AUTHOR

**Patricia Genius, MSc**

AREA

Biomarkers: Neuroimaging.

**Monday-364**

**Microglial reactivity attenuates ptau231-related amyloid accumulation in preclinical Alzheimer's disease.**

PRESENTING AUTHOR

**Wiesje Pelmans, PhD**

AREA

Biomarkers: Neuroimaging.

**Monday-394**

**Analysis of perivascular spaces highlights regional enlargement by sex, AD genetic predisposition and specific risk factors in the AD continuum.**

PRESENTING AUTHOR

**Alba Fernández-Bonet, MSc**

AREA

Biomarkers: Neuroimaging.

**Monday-397**

**Multivariate non-parametric GWAS identifies novel variants driving regional WMH through adhesion, membrane organization and neurodevelopmental pathways.**

PRESENTING AUTHOR

**Kahina Baouche, MA**

AREA

Biomarkers: Neuroimaging.

**Monday-964**

**An unsupervised remote cognitive assessment predicts mild cognitive impairment and associates to amyloid status.**

PRESENTING AUTHOR

**Clàudia Porta-Mas, MSc**

AREA

Developing Topics: Biomarkers.

**Monday-301**

**Predictors associated with rate of completion of a remote cognitive assessment.**

PRESENTING AUTHOR

**Clàudia Porta-Mas, MSc**

AREA

Biomarkers (non-neuroimaging).

**AAIC**

Monday, **July 28th** (2/2)



**POSTERS**  
(cont.)

**ONLINE**

**Exploring Associations Between Longitudinal [F]RO-948 Tau PET, Baseline Fluidtau Biomarkers, and memory in the Early Alzheimer's Disease continuum.**

PRESENTING AUTHOR

**Mahnaz Shekari, PhD**

AREA

Biomarkers: Neuroimaging.

**Monday-314**

**Plasma biomarkers predict long-term longitudinal cognitive decline in individuals at-risk for Alzheimer's disease: differences across demographic groups.**

PRESENTING AUTHOR

**Armand González-Escalante MSc**

AREA

Biomarkers (non-neuroimaging).



**FEATURED  
RESEARCH  
SESSION**

**2:00 - 3:30 pm (EDT)**

**Biological staging of Alzheimer's disease with the novel plasma eMTBR-tau243 and %p-tau217.**

PRESENTING AUTHOR

**Gemma Salvadó, PhD**

SESSION DETAILS

Insights into disease trajectory and biological staging of AD.



**ROOM 105** — Metro Toronto Convention Centre.

**AAIC**

Tuesday, July 29th (1/2)



**POSTERS**

**Tuesday-259**

**Reproductive history and cerebrovascular health: exploring the impact of childbirths on longitudinal white matter hyperintensity load and effects on cognitive outcome.**

PRESENTING AUTHOR

**Clara Gallay, MSc**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Tuesday-318**

**Detecting Amyloid- $\beta$  Pathology in Subjective Cognitive Decline using novel CSF and plasma biomarkers.**

PRESENTING AUTHOR

**José Contador, MD, PhD**

Presented by Marc Suárez-Calvet

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Tuesday-350**

**Early disclosure of Blood-Based Biomarkers optimizes Alzheimer's**

**Disease management and treatment initiation: the PLASMAR study.**

PRESENTING AUTHOR

**Isabel Estragués-Gázquez, MSc**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Tuesday-364**

**Sex-specific associations between age-related blood proteins, cognition and Alzheimer's biomarkers.**

PRESENTING AUTHOR

**Luis Felipe Hernández-Villamizar, MSc**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Tuesday-292**

**Associations between remote speech-based and paper-and-pencil cognitive assessments in individuals with Subjective Cognitive Decline.**

PRESENTING AUTHOR

**Clàudia Porta-Mas, MSc**

AREA

Biomarkers: Biomarkers (non-neuroimaging).



**AAIC**

Tuesday, **July 29th** (2/2)



**LIGHTNING  
PRESENTATION  
ROUND**

**8:00 - 8:45 am (EDT)**  **ONLINE**

**Voxel-wise longitudinal changes between amyloid PET and executive function subcomponents at the preclinical stage of the Alzheimer's continuum.**

PRESENTING AUTHOR

**Oriol Grau, MD, PhD**

SESSION DETAILS

Neuroimaging insights into clinical manifestations.

 **ROOM 106** — Metro Toronto Convention Centre.



**DEVELOPING  
TOPICS  
SESSION**

**2:00 - 3:30 pm (EDT)**

**Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology.**

PRESENTING AUTHOR

**Marc Suárez-Calvet, MD, PhD**

SESSION DETAILS

Developing Topics on Tau Biomarkers.

 **ROOM 701** — Metro Toronto Convention Centre.

**AAIC**

Wednesday, July 30th



**POSTERS**

**ONLINE**

**Late motherhood linked to accelerated memory decline in amyloid-positive cognitively unimpaired women.**

PRESENTING AUTHOR

**Anna Brugulat-Serrat, PhD**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Wednesday-460**

**Polygenic and cholesterol-related risk for white matter hyperintensities in cognitively unimpaired individuals at low cardiovascular risk for late-life dementia.**

PRESENTING AUTHOR

**Patricia Genius, MSc**

AREA

Biomarkers: Neuroimaging.

**Wednesday-386**

**Cerebral glucose metabolism and regional homogeneity as predictors of amyloid burden changes in preclinical AD.**

PRESENTING AUTHOR

**Michalis Kassinosopoulos, PhD**

AREA

Biomarkers: Neuroimaging.



**FEATURED  
RESEARCH  
SESSION**

**4:15 - 5:45 pm (EDT)**

**Distinct awareness trajectories and plasma p-tau217 accumulation over time in preclinical Alzheimer's disease.**

PRESENTING AUTHOR

**David López-Martos, MSc**

SESSION DETAILS

Awareness of Cognitive Function across the Alzheimer's disease spectrum: biological mechanisms, diagnostic, and prognostic clinical value.

📍 ROOM 105 — Metro Toronto Convention Centre.

**4:15 - 5:45 pm (EDT)**

**Diagnostic blind spot in clinical manifestations: anosognosia trajectory in preclinical Alzheimer's is linked to core pathophysiology, astrocytic reactivity, and structural changes in cognitive control and self-referential brain regions.**

PRESENTING AUTHOR

**Gonzalo Sánchez-Benavides, PhD**

SESSION DETAILS

Awareness of Cognitive Function across the Alzheimer's disease spectrum: biological mechanisms, diagnostic, and prognostic clinical value.

📍 ROOM 105 — Metro Toronto Convention Centre.